Advertisement
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
BEIJING, Jan. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading provider of biopharmaceutical products in China, announced todaythat it has received its fifth purchase order for its H1N1 vaccine,PANFLU.1(TM), from China's Ministry of Industry and Information Technology forthe national purchase plan. Under this purchase order, Sinovac is required todeliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to theChinese Central Government, of which 2.33 million doses are expected to bedelivered before March 15, 2010, and the balance of 6.23 million doses to bestockpiled by the government in Sinovac's warehouse facility.
Advertisement
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinesegovernment for a total 21.06 million doses, and 10.23 million doses ofPANFLU.1 have been delivered to date for the Chinese vaccination campaign. In2009, the Company completed the expansion of its production line used tomanufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasingits annual production capacity by approximately 60%.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Thisfifth order from the Chinese Central Government demonstrates Sinovac'scontinuing ability to complete its national H1N1 vaccine stockpiling tasks ina timely manner. The production capacity expansion has continued to serve itspurpose in positioning Sinovac to operate even more efficiently towards ourgoal of providing citizens of China with affordable, international-qualityvaccines."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemicinfluenza vaccine (H5N1) and H1N1 vaccine, have already been approved forgovernment stockpiling. Sinovac is developing vaccines for enterovirus 71,universal pandemic influenza, Japanese encephalitis, and human rabies. Itswholly owned subsidiary, Tangshan Yian, is conducting field trials forindependently developed inactivated animal
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.
------
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
BEIJING, Jan. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading provider of biopharmaceutical products in China, announced todaythat it has received its fifth purchase order for its H1N1 vaccine,PANFLU.1(TM), from China's Ministry of Industry and Information Technology forthe national purchase plan. Under this purchase order, Sinovac is required todeliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to theChinese Central Government, of which 2.33 million doses are expected to bedelivered before March 15, 2010, and the balance of 6.23 million doses to bestockpiled by the government in Sinovac's warehouse facility.
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinesegovernment for a total 20.05 million doses, and 10.23 million doses ofPANFLU.1 have been delivered to date for the Chinese vaccination campaign. In2009, the Company completed the expansion of its production line used tomanufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasingits annual production capacity by approximately 60%.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Thisfifth order from the Chinese Central Government demonstrates Sinovac'scontinuing ability to complete its national H1N1 vaccine stockpiling tasks ina timely manner. The production capacity expansion has continued to serve itspurpose in positioning Sinovac to operate even more efficiently towards ourgoal of providing citizens of China with affordable, international-qualityvaccines."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemicinfluenza vaccine (H5N1) and H1N1 vaccine, have already been approved forgovernment stockpiling. Sinovac is developing vaccines for enterovirus 71,universal pandemic influenza, Japanese encephalitis, and human rabies. Itswholly owned subsidiary, Tangshan Yian, is conducting field trials forindependently developed inactivated animal
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: [email protected] Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: [email protected] [email protected] Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.
